The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma; MSD K.K; Nippon Boehringer Ingelheim; Ono Pharmaceutical
Consulting or Advisory Role - AstraZeneca Japan; Bristol-Myers Squibb Japan; Ono Pharmaceutical
Research Funding - AstraZeneca Japan; Bristol-Myers Squibb Japan; Ono Pharmaceutical
Regorafenib plus nivolumab in patients with advanced gastric (GC) or colorectal cancer (CRC): An open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603).
 
Shota Fukuoka
Research Funding - Bayer (Inst); MSD (Inst); Ono Pharmaceutical (Inst)
 
Hiroki Hara
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Chugai Pharma; Merck Serono; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb-Ono Pharmaceutical (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Incyte (Inst); Lilly (Inst); LSK BioPharma (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Naoki Takahashi
No Relationships to Disclose
 
Takashi Kojima
Honoraria - Oncolys BioPharma
Research Funding - Astellas Amgen BioPharama (Inst); MSD (Inst); Oncolys BioPharma (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst)
 
Akihito Kawazoe
Honoraria - Bristol-Myers Squibb; Ono Pharmaceutical; Sumitomo Group; Taiho Pharmaceutical
Research Funding - Ono Pharmaceutical (Inst); Sumitomo Group (Inst); Taiho Pharmaceutical (Inst)
 
Masako Asayama
No Relationships to Disclose
 
Takako Yoshii
No Relationships to Disclose
 
Daisuke Kotani
No Relationships to Disclose
 
Hitomi Tamura
No Relationships to Disclose
 
Yuichi Mikamoto
No Relationships to Disclose
 
Ayako Sugama
No Relationships to Disclose
 
Masashi Wakabayashi
Honoraria - Chugai Pharma; Johnson & Johnson
 
Shogo Nomura
Employment - Asahi Kasei (I)
Honoraria - Taiho Pharmaceutical
 
Akihiro Sato
Honoraria - AstraZeneca; Dainippon Sumitomo Pharma
Research Funding - Aspyerian Therapeutics (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); MSD (Inst); Oncolys BioPharma (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Yosuke Togashi
No Relationships to Disclose
 
Hiroyoshi Nishikawa
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Ono Pharmaceutical
Consulting or Advisory Role - Ono Pharmaceutical
Research Funding - Asahi Kasei; Astellas Pharma; AstraZeneca; BD Biosciences; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Ono Pharmaceutical; Sysmex; Taiho Pharmaceutical; Zenyaku Kogyo
 
Kohei Shitara
Honoraria - Abbvie; Novartis; Yakult Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Lilly; MSD; Ono Pharmaceutical; Pfizer; Takeda
Research Funding - Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); Mediscience Planning (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)